Akebia Therapeutics (AKBA) Receives a Hold from Mizuho Securities

In a report released today, Mara Goldstein from Mizuho Securities maintained a Hold rating on Akebia Therapeutics (AKBAResearch Report), with a price target of $2.00. The company’s shares closed last Friday at $0.45, close to its 52-week low of $0.35.

According to, Goldstein is a 2-star analyst with an average return of 0.0% and a 33.2% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics.

The word on The Street in general, suggests a Hold analyst consensus rating for Akebia Therapeutics with a $1.75 average price target, which is a 316.7% upside from current levels. In a report issued on May 10, H.C. Wainwright also maintained a Hold rating on the stock with a $2.00 price target.

See the top stocks recommended by analysts >>

Based on Akebia Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $59.61 million and GAAP net loss of $70.68 million. In comparison, last year the company earned revenue of $56.7 million and had a GAAP net loss of $87 million.

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AKBA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Read More on AKBA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More